Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin ≥ 100 mg/m2

M. G. Kris, R. A. Clark, L. B. Tyson, W. F. Hahne, K. M.W. Pisters, R. J. Gralla

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Ondansetron, a serotonin antagonist antiemetic, controls emesis caused by cisplatin when given as multiple 0.15 mg/ kg dosages in a variety of administration schedules. This trial evaluated a single 0.45 mg/kg i.v. dose of ondansetron in 21 cancer patients receiving cisplatin at doses ≥ 100 mg/m2 as initial chemotherapy. Twenty-five percent of patients had no emetic episodes (95% confidence interval: 9-49%), and 45% had two or fewer emetic episodes (95% confidence interval: 23-69%). No significant adverse effects were seen. In prior trials at this institution in similarly treated patients, ondansetron given in three divided doses yielded a 42% no emesis rate. In this trial a single i.v. 0.45 mg/kg dose of ondansetron prevented emesis in 25% of patients receiving initial cisplatin ≥ 100 mg/m2. For this dose of cisplatin and ondansetron, the observed emesis complete control rate was lower than that previously seen using multiple dose schedules.

Original languageEnglish (US)
Pages (from-to)77-80
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume16
Issue number1
DOIs
StatePublished - Jan 1 1993

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin ≥ 100 mg/m<sup>2</sup>'. Together they form a unique fingerprint.

  • Cite this